direct-acting antivirals
Psychiatric treatment considerations with direct acting antivirals in hepatitis C
... Treatment of hepatitis C virus (HCV), a virus infecting over 170 million worldwide [1], has evolved over the last two decades and moved from interferon-alpha mono- therapy to pegylated interferon-alpha (IFN α ) in ...
10
Managing HIV/hepatitis C co-infection in the era of direct acting antivirals
... the direct fibrogenetic ef- fect of HIV in the liver and a likely consequence of HIV induced impairment of the innate and adaptive immune system leading to more inflammation, apoptosis and fi- brosis ...of ...
9
Predictors of Direct Acting Antivirals Failure in Patients with Chronic Hepatitis C Virus in Ivory Coast: About 5 Cases
... Aim: Direct-acting antivirals are the therapeutic revolution in the management of viral hepatitis C, but often with a few cases of ...of direct-acting antiviral therapy in patients with ...
9
A case series evaluating the impact of Hepatitis C eradication using direct acting antivirals on primary biliary cholangitis-associated autoimmunity
... Although not common, patients with primary biliary cholangitis (PBC) and concurrent HCV infection (PBC-HCV) have been previously described [8, 9]. PBC-HCV patients appear to have more aggressive liver disease, as ...
6
Ribavirin Concentrations, Laboratory Variables, and Clinical Outcomes During Treatment of Hepatitis C Infection with First Generation Direct-Acting Antivirals
... Abstract: In treating hepatitis C infection, identification of reliable markers predicting virological non-response appear central to improving outcome and to prompting changes in dynamic treatment approaches. The ...
7
The Australasian Hepatology Association consensus guidelines for the provision of adherence support to patients with hepatitis C on direct acting antivirals
... subsidizing direct acting antivirals (DAAs) for the treatment of hepatitis C, which are highly effective (95% cure rate) and have few side ...
11
Hepatitis C Virus Variants with Decreased Sensitivity to Direct-Acting Antivirals (DAAs) Were Rarely Observed in DAA-Naive Patients prior to Treatment
... T he hepatitis C virus (HCV) NS3-4A protease, NS5A protein, and NS5B polymerase are essential for viral replication. Inhib- itors of their function comprise the vanguard of a new class of HCV inhibitors, namely, ...
10
Impact of hepatitis C virus genotype-4 eradication following direct acting antivirals on liver stiffness measurement
... Recently, direct acting antivirals (DAAs), medicines with direct activity against HCV, were introduced for treatment of HCV with very favorable ...
9
Effectiveness of Treatment of Chronic Viral Hepatitis C by Direct Acting Antivirals in Togo
... Direct-acting antivirals have revolutionized the management of viral hepatitis C in the world and in Togo in particular. These drugs offer the possibility of oral therapy without interferon. This ...
9
Mayrthaler, Laura (2019): Next Generation Sequencing as screening method for resistance associated variants in Hepatitis C Virus before treatment with direct acting antivirals. Dissertation, LMU München: Medizinische Fakultät
... Weltweit sind mehr als 170 Millionen Menschen mit dem Hepatitis C Virus infiziert. Dank der 2011 auf den Markt gekommenen direct acting antivirals (DAAs) hat sich die Therapie von Patienten mit ...
133
DIRECT ACTING ANTIVIRALS IN HEPATITIS C INFECTION: DEVELOPING A PERSONALISED MODEL OF CARE
... Despite the dramatic success of DAA development, challenges remain on the path to cure. In 2011, boceprevir and telaprevir became the first direct acting antivirals approved for the treatment of HCV ...
240
<p>The Utility of Retinol-Binding Protein 4 in Predicting Liver Fibrosis in Chronic Hepatitis C Patients in Response to Direct-Acting Antivirals</p>
... In this study, we evaluated the performance of fi ve indices in predicting liver fi brosis grade, and we found that with the increasing hepatic fi brosis severity, as estimated by fi broscan[r] ...
11
The potential impact of a hepatitis C vaccine for people who inject drugs: is a vaccine needed in the age of direct-acting antivirals?
... Results UK impact projections: vaccine For the baseline UK scenario 40% chronic prevalence, annual vaccination rates of 100 per 1000 PWID could achieve a relative prevalence reduction am[r] ...
19
Hepatitis C in the era of direct acting antivirals: real world costs of untreated chronic hepatitis C; a cross sectional study
... licensed direct acting anti-virals (DAA ’ s) significantly improve the treatment outcomes for patients with HCV genotype 1 infection and further novel agents promise a paradigm shift in the treatments and ...
9
Pegylated-interferon plus ribavirin treatment does not alter the prevalence of resistance-associated substitutions to direct-acting antivirals in HCV genotype 1a patients
... To determine the prevalence of clinically relevant RASs in P/R treatment failure patients and whether P/R treatment has an effect on these RASs in a cross-sectional study, we compared[r] ...
7
Effectiveness of triple therapy with direct acting antivirals for hepatitis C genotype 1 infection: application of propensity score matching in a national HCV treatment registry
... directly acting antiviral (DAA) agents telaprevir (TPV) and boceprevir (BOC), for use in combination with pegylated-interferon and ribavirin (PR), changed the opti- mal treatment regimen for genotype (GT) 1 HCV ...
10
Interpreting discordant indirect and multiple treatment comparison meta-analyses: an evaluation of direct acting antivirals for chronic hepatitis C infection
... No guidance exists to assess methodologies that lead to different results. In this article, methodological issues that should be considered when interpreting comparative ITC or MTC meta-analyses are reviewed using the ...
11
Establishing the cascade of care for hepatitis C in England benchmarking to monitor impact of direct acting antivirals
... Funding The research received funding from the National Institute for Health Research Health Protection Research Unit [NIHR HPRU] in Blood Borne and Sexually Transmitted Infections at UC[r] ...
24
Neuropsychiatric performance and treatment of hepatitis C with direct acting antivirals: a prospective study
... When quantitative neuropsychiatric measures were analysed over time, at T2 the end of the course of DAAs treatment patients with cirrhosis exhibited a significant slowing in choice react[r] ...
7
Hepatitis C virus pharmacogenomics in Latin American populations: implications in the era of direct-acting antivirals
... new direct-acting antiviral agents (DAAs) represent a great hope for millions of chronically infected individuals because their use may lead to excel- lent cure rates with fewer side ...
13